Prospective evaluation of ustekinumab(UST)- effects in patients with ulcerative colitis

Prospective evaluation of ustekinumab (UST)- effects in patients with ulcerative colitis - UST UC Cohort Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039946

Enrollment

Registered

2020-05-11

Start date

2020-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: UC patients who will be treated with ustekinumab in our hospital

Exclusion criteria

Exclusion criteria: 1. Patients without informed consent 2. Patients determined to be inappropriate for this study by doctor

Design outcomes

Primary

Measure	Time frame
Persistence of ustekinumab at week 56	—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology

skato@saitama-med.ac.jp049-228-3564

Outcome results